Coronary interventions

Cystatin C and risk of mortality among patients undergoing percutaneous coronary intervention

EuroIntervention 2015;11:757-764 published online ahead of print August 2014. DOI: 10.4244/EIJY14M08_02

Fabio Angeli
Fabio Angeli1*, MD; Paolo Verdecchia2, MD; Stefano Savonitto3, MD; Gustavo Arraiz4, MSc; Martina Zaninotto5, MD; Andrea Broccatelli1, MD; Chiara Cosma5, PhD; Stefano De Servi6, MD; Federico Sabino7, MD; Carlo Briguori8, MD; Giuseppe Ambrosio1, MD; Claudio Cavallini1, MD; on behalf of the Italian “Atherosclerosis, Thrombosis and Vascular Biology” and “Society for Invasive Cardiology-GISE” Investigators
1. Azienda Ospedaliera ed Universitaria di Perugia, Perugia, Italy; 2. Ospedale di Assisi, Assisi, Italy; 3. Ospedale A. Manzoni, Lecco, Italy; 4. Sintesi Research S.r.l., Milan, Italy; 5. Università degli studi di Padova, Padua, Italy; 6. Fondazione Poli

Aims: We tested the prognostic value of cystatin C in patients with documented coronary artery disease (CAD) who underwent percutaneous coronary artery intervention (PCI). We also tested

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

coronary artery diseasecystatin cestimated glomerular filtration ratepercutaneous transluminal coronary interventionprognosisreceiver-operating characteristic curve analysis
Read next article
Facilitated patent haemostasis after transradial catheterisation to reduce radial artery occlusion

Latest news